Sun Pharmaceutical Industries is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures pharmaceutical formulations and active pharmaceutical ingredients and sells products in more than 100 countries.
The liposomal doxorubicin market is projected to grow from $1.32 billion in 2025 to $1.77 billion by 2030, while the broader breast cancer drugs market is expected to reach $54.49 billion by 2036. Growth is driven by increasing cancer incidence, adoption of targeted therapies, and advancements in drug delivery systems including liposomal formulations and antibody-drug conjugates.
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05669339 |
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma |
RECRUITING | PHASE2 |
| NCT04679480 |
Anti-PD1-antibody and Pulsed HHI for Advanced BCC |
ACTIVE_NOT_RECRUITING | PHASE2 |
